Cryomass Technologies

Cryomass Technologies FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cryomass Technologies (CRYM) as of Nov 19, 2026 is 29.94 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 49.57 % — a change of -39.60% (lower).

FCF Conversion

29.94 %

YoY

-39.60%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cryomass Technologies is 2023 29.94 % . FCF Conversion Rate (FCF/EBITDA) of Cryomass Technologies was 2022 49.57 % . It decreases by -39.60% lower compared to the previous year.

The Cryomass Technologies FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
0.00 USD
Jan 1, 2017
804.24 USD
Jan 1, 2018
221.88 USD
Jan 1, 2019
98.78 USD
Jan 1, 2020
42.10 USD
Jan 1, 2021
53.08 USD
Jan 1, 2022
49.57 USD
Jan 1, 2023
29.94 USD
The Cryomass Technologies FCF Conversion history
YEARFCF ConversionYoY
29.94 %-39.60%
49.57 %-6.60%
53.08 %+26.07%
42.10 %-57.38%
98.78 %-55.48%
221.88 %-72.41%
804.24 %—
0.00-100.00%
166.67 %+316.67%
40.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cryomass Technologies Stock analysis

What does Cryomass Technologies do? CryoMass Technologies, Inc. operates medical marijuana dispensaries and related businesses, leveraging patented technology that utilizes liquid nitrogen to separate, collect, and protect high-value compounds from harvested plants. The firm owns a Trichome Separation unit, known as the CryoMass patented liquid nitrogen system, which is optimized for capturing fully intact cannabis and hemp trichomes along with terpenes. This system stabilizes and collects trichomes at harvest, preventing wasteful loss and functioning effectively within minutes after plants are cut or on fresh frozen and dried plant parts including trim. The company generates revenue by selling its proprietary Trichome Separation system to entities involved in the cultivation and processing of cannabis and hemp. By offering a solution that efficiently captures valuable compounds from various plant states, CryoMass Technologies targets customers seeking to maximize yield and quality in the medical marijuana sector. The business model relies on the unique capabilities of its liquid nitrogen technology to provide a superior alternative to traditional extraction methods, appealing to dispensaries and related businesses looking to enhance their operational efficiency and product integrity. Cryomass Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cryomass Technologies stock

FCF Conversion Rate (FCF/EBITDA) of Cryomass Technologies is 29.94 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Cryomass Technologies changed from 49.57 % to 29.94 %, representing a -39.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cryomass Technologies since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cryomass Technologies with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cryomass Technologies

All Key Metrics — Cryomass Technologies